What is XRTX's current stock price?

XRTX (XORTX Therapeutics Inc.) is currently trading at $2.18 with a market cap of $607.1K.

What sector is XORTX Therapeutics Inc. in?

XORTX Therapeutics Inc. (XRTX) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

XRTX XORTX Therapeutics Inc.

Healthcare

$2.18-4.18%ClosedMarket Cap: $607,106

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.39

P/S

0.00

EV/EBITDA

-0.13

DCF Value

$3.44

FCF Yield

-349.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-135.3%

ROA

-128.3%

ROIC

-238.9%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-797.3K	$—
Q4 null	$0.00	$-590.5K	$—
FY null	$0.00	$-2.7M	$—
Q3 null	$0.00	$-649.5K	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.73

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.

Peers